Vasiliki Leventaki, MD
Vasiliki Leventaki, MD

Vasiliki Leventaki, MD

Assistant Member, St. Jude Faculty

Departments

Education

MD – National and Kapodistrian University of Athens, Athens, Greece
Residency (Anatomic and Clinical Pathology) - University of Utah, Salt Lake City, Utah
Fellowship (Hematopathology) - UT MD Anderson Cancer Center, Houston, Texas

Research Interests

  • The use of high-resolution genomic methods to identify novel and recurrent genomic aberrations in different types of pediatric lymphoma and their correlation with disease progression and treatment outcome.
  • Investigation of the biological mechanisms by which specific genomic alterations in pediatric lymphomas contribute to tumor development.

Selected Publications

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia Jul;31(7):1633-1637, 2017.

Palacios G, Shaw T, Li Y, Singh RK, Valentine M, Sandlund JT, Lim MS, Mullighan CG, Leventaki V. Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. Leukemia Mar;31(3):743-747, 2017.

Pan Y, Wang S, Su B, Zhou F, Zhang R, Xu T, Zhang R, Leventaki V, Drakos E, Liu W, Claret FX. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. Oncogene Feb 23;36(8):1069-1079, 2017.

Helton KJ, Maron G, Mamcarz E, Leventaki V, Patay Z, Sadighi Z. Unusual magnetic resonance imaging presentation of post-BMT cerebral toxoplasmosis masquerading as meningoencephalitis and ventriculitis. Bone Marrow Transplant Nov;51(11):1533-1536, 2016.

Ferguson-Paul K, Mangum S, Porter A, Leventaki V, Campbell P, Wolf J. Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis. Emerg Infect Dis Jun;22(6):1119-21, 2016.

Ok CY, Leventaki V, Wang SA, Dinardo C, Medeiros LJ, Konoplev S. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol Feb;145(2):271-6, 2016.

Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia Nov;29(11):2162-72, 2015.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol Nov;167(4):514-23, 2014.

Leventaki V, Drakos E, Karanikou M, Psatha K, Lin P, Schlette E, Eliopoulos A, Vassilakopoulos TP, Papadaki H, Patsouris E, Medeiros LJ, Rassidakis GZ. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum Pathol Mar;45(3):565-72, 2014.

Leventaki V, Manning JT Jr, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol Feb;45(2):421-6, 2014.

Kunkalla K, Liu Y, Qu C, Leventaki V, Agarwal NK, Singh RR, Vega F. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol Jun;92(6):777-87, 2013.

Leventaki V*, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol 158(6):763-771, 2012. *This work was partially supported by a Resident Research Grant from the College of American Pathologists Foundation.

Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymph 53(9):1839-1841, 2012.

Last update: October 2017